CN109789117B - 治疗急性肾损伤的方法 - Google Patents

治疗急性肾损伤的方法 Download PDF

Info

Publication number
CN109789117B
CN109789117B CN201780062021.8A CN201780062021A CN109789117B CN 109789117 B CN109789117 B CN 109789117B CN 201780062021 A CN201780062021 A CN 201780062021A CN 109789117 B CN109789117 B CN 109789117B
Authority
CN
China
Prior art keywords
compound
acute kidney
kidney injury
pharmaceutically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780062021.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109789117A (zh
Inventor
B·拉古
M·帕塔内
E·托佐
S·特扎斯卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Engineered Small Molecules US Inc
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of CN109789117A publication Critical patent/CN109789117A/zh
Application granted granted Critical
Publication of CN109789117B publication Critical patent/CN109789117B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
CN201780062021.8A 2016-10-05 2017-10-05 治疗急性肾损伤的方法 Active CN109789117B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404390P 2016-10-05 2016-10-05
US62/404,390 2016-10-05
PCT/US2017/055400 WO2018067857A1 (en) 2016-10-05 2017-10-05 Methods of treating acute kidney injury

Publications (2)

Publication Number Publication Date
CN109789117A CN109789117A (zh) 2019-05-21
CN109789117B true CN109789117B (zh) 2022-08-23

Family

ID=60153507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780062021.8A Active CN109789117B (zh) 2016-10-05 2017-10-05 治疗急性肾损伤的方法

Country Status (33)

Country Link
US (1) US20210283116A1 (cg-RX-API-DMAC7.html)
EP (1) EP3522880B1 (cg-RX-API-DMAC7.html)
JP (1) JP7065839B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190062502A (cg-RX-API-DMAC7.html)
CN (1) CN109789117B (cg-RX-API-DMAC7.html)
AU (1) AU2017340760B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005539A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036723A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019004561A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124759T1 (cg-RX-API-DMAC7.html)
DK (1) DK3522880T3 (cg-RX-API-DMAC7.html)
ES (1) ES2859487T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210294T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053557T2 (cg-RX-API-DMAC7.html)
IL (1) IL265749A (cg-RX-API-DMAC7.html)
JO (1) JOP20190056B1 (cg-RX-API-DMAC7.html)
LT (1) LT3522880T (cg-RX-API-DMAC7.html)
MA (1) MA46459B1 (cg-RX-API-DMAC7.html)
MD (1) MD3522880T2 (cg-RX-API-DMAC7.html)
MX (1) MX387518B (cg-RX-API-DMAC7.html)
MY (1) MY192385A (cg-RX-API-DMAC7.html)
PH (1) PH12019500725A1 (cg-RX-API-DMAC7.html)
PL (1) PL3522880T3 (cg-RX-API-DMAC7.html)
PT (1) PT3522880T (cg-RX-API-DMAC7.html)
RS (1) RS61573B1 (cg-RX-API-DMAC7.html)
RU (1) RU2753607C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201901925RA (cg-RX-API-DMAC7.html)
SI (1) SI3522880T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100111T1 (cg-RX-API-DMAC7.html)
TW (1) TWI778982B (cg-RX-API-DMAC7.html)
UA (1) UA124019C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018067857A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201901743B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016333963C1 (en) 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US11358954B2 (en) * 2016-04-13 2022-06-14 Mitobridge, Inc. PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN109843857B (zh) * 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
WO2021013772A1 (en) 2019-07-19 2021-01-28 Vifor (International) Ag Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
CA3212825A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN115813901B (zh) * 2022-10-20 2024-10-22 南京市儿童医院 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802622A (zh) * 2009-05-14 2012-11-28 艾雪米克斯公司 用于治疗缺血和缺血再灌注损伤的组合物和方法
CN105324395A (zh) * 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN105917229A (zh) * 2013-12-03 2016-08-31 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539403C (en) 2003-09-19 2013-11-19 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
RU2320341C1 (ru) * 2006-06-13 2008-03-27 Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук Средство для лечения острой обструкции верхних мочевыводящих путей
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
JP2016520552A (ja) * 2013-04-05 2016-07-14 ソーク インスティテュート フォー バイオロジカル スタディーズ Pparアゴニスト
EP2862574A1 (en) 2013-10-15 2015-04-22 Sanofi {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
AU2016333963C1 (en) * 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802622A (zh) * 2009-05-14 2012-11-28 艾雪米克斯公司 用于治疗缺血和缺血再灌注损伤的组合物和方法
CN105324395A (zh) * 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法
CN105917229A (zh) * 2013-12-03 2016-08-31 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Peroxisome Proliferator-Activated Receptorδ Agonist,HPP593, Prevents Renal Necrosis under Chronic Ischemia;Larisa V. Fedorova et al.;《PLOS ONE》;20130503;e64436(第1-13页) *

Also Published As

Publication number Publication date
AU2017340760A1 (en) 2019-03-21
PL3522880T3 (pl) 2021-08-23
CY1124759T1 (el) 2022-07-22
ES2859487T3 (es) 2021-10-04
RU2019111421A (ru) 2020-11-06
JP2019533660A (ja) 2019-11-21
ZA201901743B (en) 2022-04-28
MA46459B1 (fr) 2021-03-31
MA46459A (fr) 2019-08-14
AU2017340760B2 (en) 2023-07-27
MY192385A (en) 2022-08-18
MX2019003949A (es) 2019-06-10
PT3522880T (pt) 2021-02-22
RS61573B1 (sr) 2021-04-29
SG11201901925RA (en) 2019-04-29
JOP20190056A1 (ar) 2019-03-24
CN109789117A (zh) 2019-05-21
RU2019111421A3 (cg-RX-API-DMAC7.html) 2021-02-05
UA124019C2 (uk) 2021-07-07
EP3522880B1 (en) 2020-12-02
WO2018067857A1 (en) 2018-04-12
TWI778982B (zh) 2022-10-01
MD3522880T2 (ro) 2021-03-31
PH12019500725A1 (en) 2019-08-05
SMT202100111T1 (it) 2021-05-07
LT3522880T (lt) 2021-03-25
DK3522880T3 (en) 2021-01-18
TW201815391A (zh) 2018-05-01
MX387518B (es) 2025-03-18
RU2753607C2 (ru) 2021-08-18
CO2019004561A2 (es) 2019-07-31
KR20190062502A (ko) 2019-06-05
JP7065839B2 (ja) 2022-05-12
BR112019005539A2 (pt) 2019-06-18
SI3522880T1 (sl) 2021-07-30
JOP20190056B1 (ar) 2022-03-15
IL265749A (en) 2019-06-30
HRP20210294T1 (hr) 2021-04-16
HUE053557T2 (hu) 2021-07-28
EP3522880A1 (en) 2019-08-14
CA3036723A1 (en) 2018-04-12
US20210283116A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
JP7065839B2 (ja) 急性腎障害を処置する方法
JP2022537570A (ja) がんを処置する方法
CN104023723B (zh) 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物
US10029956B2 (en) Therapies for cancer using isotopically substituted lysine
JP2023529011A (ja) インデン化合物、その医薬組成物、及びそれらの治療応用
WO2010135972A1 (zh) 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途
EP3730509B1 (en) Compound for treating metabolic diseases and preparation method and use thereof
JP2018515454A (ja) 尿酸輸送体阻害剤のナトリウム塩およびその結晶形
US9550733B2 (en) Fluorinated derivatives of 3-hydroxypyridin-4-ones
JP5290190B2 (ja) イミダゾール−5−カルボン酸誘導体の塩、製造方法及びその医薬組成物
HK40008682B (en) Methods of treating acute kidney injury
HK40008682A (en) Methods of treating acute kidney injury
CA3195597A1 (en) Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders
EP3305293A1 (en) Method for treating or preventing diabetic nephropathy
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
US20250361243A1 (en) Compounds and Pharmaceutical Compositions Useful for Managing Sickle Cell Disease and Conditions Related Thereto
CN110066258A (zh) 噻唑-5-甲酸衍生物及其制备方法与应用
CN111447932A (zh) 含有1,4-苯并硫氮杂*-1-氧化物衍生物的光学异构体的肾功能障碍的改善药
CN115003653A (zh) 艾拉菲诺的多晶型物
JP2018535243A (ja) ダニリキシンの静脈内注射用製剤
CN116648445A (zh) 治疗或预防慢性肾脏病的方法
HK40096745A (en) Methods for treating or preventing chronic kidney disease
CN112441916A (zh) 新型苯乙酸衍生物、其制备方法及其作为药物的用途
JPH0676324B2 (ja) 糖ラクタムを含有する抗炎症剤
JPS634807B2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008682

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant